BACKGROUND: For women undergoing breast conservation therapy (BCT), the added value of breast magnetic resonance imaging (MRI) at the time of initial diagnosis remains controversial. The current study was performed to determine long-term outcomes after BCT for women with and without pretreatment breast MRI. METHODS: Between 1992 and 2001, a total of 755 women with ductal carcinoma in situ or early-stage invasive breast cancer underwent breast-conserving surgery (with axillary lymph node staging for invasive carcinoma) followed by definitive breast radiotherapy. Evaluation at the time of the initial diagnosis included conventional mammography in all subjects and breast MRI in 215 women (28%). Clinical, pathologic, and treatment characteristics were comparable for patients with and without breast MRI. Outcomes were determined using the Kaplan-Meier method and compared using the log-rank method. RESULTS: At a median follow-up of 13.8 years, there were 49 local failures (15 women with and 34 women without breast MRI, respectively). The 15-year local failure rates were 8% for women with and 8% for women without MRI (P 5.59). There also were no differences noted between women with and without breast MRI with regard to 15-year rates of overall survival (77% vs 71%; P 5.24), freedom from distant metastases (86% vs 90%; P 5.08), and contralateral breast cancer (10% vs 8%; P 5.10). Multivariate analysis demonstrated no significant impact of breast MRI on local failure (P 5.96). CONCLUSIONS: Breast MRI during the initial evaluation for BCT appears to have no significant impact on 15-year rates for local control, overall survival, freedom from distant metastases, or contralateral breast cancer. The routine use of pretreatment breast MRI is not indicated for patients undergoing BCT. Cancer 2017;123:1324-32.
INTRODUCTION
The acceptance of breast conservation therapy (BCT) with breast-conserving surgery (BCS) and definitive breast irradiation as an equal rather than lesser alternative to mastectomy was a seminal step in oncologic management. [1] [2] [3] [4] To help establish the objective suitability of BCT for a patient with breast cancer, the primary imaging modality of choice remains mammography. 5 However, breast magnetic resonance imaging (MRI) can detect cancerous foci that are not identified in mammograms, especially in younger women and in patients with dense breast tissue or invasive lobular carcinoma. [5] [6] [7] [8] [9] [10] [11] Consequently, this technology has been used increasingly to evaluate candidates for BCT, despite position statements and guidelines from professional societies advocating for the use of MRI only in select clinical situations. 5, [12] [13] [14] The rationale for the use of preoperative MRI in the BCT population has been that superior delineation of the extent of disease will be beneficial for tailoring and optimizing the extent of surgery and radiotherapy, thereby improving local control. Caveats regarding the routine use of MRI in evaluating patients with breast cancer include its limited specificity and its known association with unnecessary biopsy procedures, treatment delays, and overtreatment in the form of increased mastectomy rates, all at a greater financial cost to society and emotional cost to the patient. 5, 12, 13 Furthermore, the remarkably low rate of local failure (LF) and excellent cause-specific survival (CSS) and overall survival (OS) rates associated with BCT are compelling factors to consider when debating the merits of any addition to the routine staging of patients with breast cancer. Ultimately, the long-term clinical significance and impact of additional disease detected using breast MRI needs to be established to better ascertain its value in preoperative evaluation.
The current study assessed the potential long-term value of integrating breast MRI into the clinical evaluation of women with newly diagnosed, early-stage invasive breast carcinoma or ductal carcinoma in situ (DCIS). We have previously reported 8-year results, 15 and herein have provided 15-year outcome data.
MATERIALS AND METHODS

Patient and Treatment Details
The study population consisted of 755 women who underwent BCS followed by definitive breast irradiation at the Hospital of the University of Pennsylvania (HUP) between 1992 and 2001. Inclusion criteria to define the study population have been reported previously. 15 One duplicate record from the data set of the prior publication 15 was found and removed. All women had unilateral DCIS or early-stage invasive breast carcinoma and were eligible for BCT. Routine breast imaging included conventional mammography with correlation ultrasound as indicated. Beginning in the early 1990s, breast MRI was integrated into the workup and evaluation for some patients with newly diagnosed invasive carcinoma or DCIS who were being evaluated for BCT at HUP. Thus, although the current study is a retrospective review of nonrandomized study subjects, the study period was intentionally set at 1992 to capture patients both with and without a preoperative breast MRI who were managed in the same era. Consequently, of the 755 study patients, 215 (28%) also had undergone a breast MRI examination at the time of their initial breast cancer diagnosis and evaluation; the remaining 540 patients (72%) had not. All breast MRI studies were performed in the radiology department at HUP; the technical method has been well described. [16] [17] [18] [19] [20] [21] Clinical and radiologic findings were available to the radiologist at the time of breast MRI interpretation and, whenever performed, the breast MRI was considered a potential source of information to aid in clinical management. Patients with synchronous bilateral breast cancers at the time of presentation were excluded from analysis regardless of the means of detection.
BCT as performed at HUP has been well described. 15, [22] [23] [24] [25] [26] [27] Briefly, definitive locoregional treatment for all women consisted of breast-conserving lumpectomy followed by definitive breast irradiation. Surgical treatment included primary tumor excision with re-excision(s) as indicated. Pathologic axillary lymph node staging was performed for all patients with invasive carcinoma. Definitive-intent radiotherapy was delivered to the whole breast with a boost to the primary tumor bed for all patients, for a total dose of 60 Gray (Gy) minimum (median, 63 Gy and mean, 62.58 Gy; range, 60-68 Gy). Regional lymph node irradiation was added as clinically indicated at the discretion of the treating physician, generally for patients with pathologically positive lymph nodes.
Adjuvant systemic therapy was delivered as clinically indicated based on patient and tumor characteristics. Among patients who received adjuvant hormonal treatment, the overwhelming majority received adjuvant tamoxifen. The study period predated the routine use of adjuvant aromatase inhibitors for postmenopausal patients or trastuzumab for patients with human epidermal growth factor receptor 2 (HER2)-positive tumors.
Statistical Design and Analysis
Descriptive statistics were computed for patient and tumor characteristics. Clinical outcomes analyzed included OS (deaths from any cause were considered as events), CSS (only deaths due to breast cancer were considered as events; non-breast cancer deaths and unknown causes of death were considered as competing risk events), time to LF as recurrence of disease within the treated breast (DCIS and invasive LF were considered as events), freedom from distant metastases (FFDM; considered as a failure at the time of first evidence of distant metastatic disease), and the development of a contralateral breast cancer (CLB; DCIS and invasive cancer were considered as events). For analysis of CSS and FFDM, a patient who developed a non-breast second malignant neoplasm (other than nonmelanoma skin cancer) was censored at the time of occurrence of the second malignant neoplasm. Kaplan-Meier curves were used to calculate outcomes for OS, FFDM, LF, and CLB whereas cumulative incidence function was computed for CSS. 28 The multiple imputation approach was used with 30 imputations to address deaths with unknown causes (approximately 35% of deaths). 29, 30 The time period was calculated as beginning at the initiation of definitive breast irradiation (not at the time of diagnosis of breast carcinoma) through the event or date of last follow-up. The log-rank test was used for equality of survival or failure functions between groups, and the Gray test was used for comparison of CSS curves. 31 The multivariate Cox proportional hazards model was used to estimate hazard ratios (HRs) while adjusting unbalanced patient and tumor characteristics at baseline or other confounders. 32, 33 No violation of the proportional hazards assumption was found by a score test based on scaled Schoenfeld residuals. The Fine-Gray regression model was used to estimate the subdistribution HRs for CSS. 34, 35 A P value < .05 was considered to be statistically significant.
RESULTS
The median follow-up for all patients was 13.8 years (mean, 12.7 years; range, 0.1-23.6 years). The median Outcomes according to the use of breast MRI are shown in Table 2 . There were no differences noted between the 2 groups with regard to any of the clinical endpoints evaluated (all P .08). There were 49 LFs (15 among women with and 34 among women without breast MRI). The 15-year LF rates were 8% (95% confidence interval [95% CI], 4%-13%) for women with a breast MRI and 8% (95% CI, 5%-11%) for women without a breast MRI (P 5 .59) (Fig. 1 ). There also were no differences observed between women with and without breast MRI with regard to 15-year rates of OS (77% vs 71%), FFDM (83% vs 89%), and CLB (10% vs 8%) (all P .08) (Fig. 2) .
Predictive Factors and Clinically Relevant Subsets
Multivariate analysis was performed to evaluate the impact of variables on rates of LF and CLB ( (Table 3) or on OS, CSS, or FFDM (data not shown).
Clinically relevant patient subsets with sufficient 5-year data also were examined (Table 4) . After stratifying by histology, patient age, and biologic subtypes based on hormone receptor groupings, there continued to be no difference noted between the 2 groups with regard to any LF (all P .07).
DISCUSSION
Through 15 years of follow-up in women with DCIS or early-stage invasive breast cancer who were managed with initial BCT, the use of breast MRI was not found to be associated with an improvement in clinical outcomes. The findings from the current study reflect updated 15-year results that extend and remain consistent with those of our original report. 15 The dual and often competing goals of BCT are to optimize local control of disease while minimizing the extent of normal tissue resection, thereby mitigating the potential postoperative, cosmetic, and psychological consequences. Eligible patients ideally should have unicentric tumors based on physical examination and mammography; however, these clinical tools have known limitations with regard to sensitivity. In fact, pathologic review of mastectomy specimens often reveals microscopic disease foci outside of the region that typically would be excised in a BCS procedure (ie, the surgical volume of the primary tumor plus a cosmetically acceptable margin) 24, 25 , and hence the justification for postlumpectomy breast radiotherapy. The additive ability of advanced pretreatment breast imaging technologies such as MRI to better identify these otherwise clinically occult multifocal or multicentric foci is not in question, but rather the value of such information. The hypothesis supporting a potential benefit is that improved visualization of disease with MRI identifies more extensive disease in some patients, enabling better selection of optimal candidates for BCS versus mastectomy, all of which ultimately may lead to better outcomes oncologically as well as esthetically.
However, in the current study of patients with earlystage disease who underwent BCT, there was no clinical improvement in the 15-year outcomes measured noted with the use of breast MRI. This is perhaps not surprising given the ability of whole breast radiation to successfully eradicate microscopic foci of residual, unresected disease in the majority of patients, regardless of whether the foci were detected and known. A solid body of level 1 evidence demonstrates that the addition of radiation after BCS substantially improves local control, and also provides a small but significant improvement in survival for patients with invasive breast carcinoma. 1, 3, 4 The use of MRI to determine suitability for BCS alone or, conversely, to support whole-breast radiation after BCS or otherwise mastectomy would not be expected to overcome the existing therapeutic limitations that affect all patients regardless of pretreatment imaging. Just as mastectomy does not lead to 100% local control in patients with early-stage invasive breast cancer, neither does BCS alone in wellselected patients, even those with negative surgical margins. Similarly, there is a small but notable subset of patients treated with BCT who will develop local disease recurrence despite postoperative radiotherapy. Ultimately, retention of the breast will always leave the patient with a finite risk of LF through the development of a new primary tumor of the breast or failure of primary treatment. Abbreviations: 95% CI, 95% confidence interval; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging.
Patients with any unknown hormone receptors status or unknown HER2 status were excluded. a P values were determined using the log-rank test. b The group that was hormone receptor negative and HER2 positive was not shown due to small numbers. There are several other reasons why MRI may carry a more limited appeal for patients treated with BCT and their providers in the future. As advanced breast imaging capabilities such as digital tomography and its 3-dimensional assessment are integrated into current mammography protocols, 36 the additive value of MRI may be rendered less certain. Recently reported data on declining rates of local recurrence over time, 37, 38 in part associated with the increasing use of effective systemic therapies, may further undermine the additive value of MRI at the time of initial evaluation among patients treated with BCT. Despite enhancements in MRI technology over the years, the era of radiotherapy over the time period studied did not alter the nonsignificant P value for the MRI variable (Table 3 ). There also was no statistical evidence of an interaction between the year of radiotherapy, as a proxy for improving technology, and MRI use on the risk of local control (P 5 .7).
In addition, we evaluated clinically relevant subsets and were unable to find differences in LF between patients with or without breast MRI based on histopathology of the primary tumor (invasive vs DCIS), patient age (50 years or < 50 years), or hormonal receptor status. We lacked sufficient data regarding invasive lobular cancer, although this entity as well as patient age have been investigated and found to lack any statistically significant interaction, thereby suggesting a benefit with the addition of MRI to standard clinical, conventional imaging and pathological assessments. 39 Among the assessable biologic subtypes, the outcomes of patients with triple negative disease are notable for a possible trend toward a local control benefit with MRI (P 5 .07). Although the sample size in this receptor subcategory is relatively small, these data are consistent with our previously reported analyses of patients with triple negative disease, 40 and partly support the ongoing Alliance MRI study (ClinicalTrials.gov identifier NCT01805076) for patients with hormone receptor-negative clinical stage I to II breast cancer.
The findings of the current study are consistent with those of what to the best of our knowledge are the few available studies that also have primarily investigated the impact of MRI on local disease recurrence after BCT, each of which demonstrated no significant difference associated with MRI for patients with invasive breast cancer, 41 DCIS, 42 or both. 43 Furthermore, an individualized person data meta-analysis testing the association between preoperative breast MRI and local and distant disease recurrence demonstrated no value with MRI. 44 One small study did indicate value with MRI, but had high rates of local disease recurrence and CLB in the group of patients who did not receive MRI at a mean follow-up of only approximately 40 months. 45 To our knowledge, the current study provides the longest follow-up reported to date in the literature.
The current study has several limitations, the most important of which is its nonrandomized, retrospective nature. Analysis of a patient cohort from a single institution introduces the possibility of selection bias in the receipt of MRI; it is interesting to note that breast MRI was more commonly obtained for younger patients ( Table 1) . As mentioned, we excluded patients with synchronous bilateral breast cancers at the time of presentation regardless of how these tumors were detected; this may introduce a potential, albeit extremely small, bias, given that the estimated number of such patients is very low. Furthermore, we lacked data regarding the value of MRI in potential BCT candidates who were noted to have extensive disease on MRI and thus were treated with mastectomy. However, this would potentially introduce a bias wherein the patients who received MRI would, if anything, be expected to do better. For those patients who did still proceed with BCT, it is similarly difficult to assess the impact of more extensive disease noted on MRI on a surgeon's decision to perform a slightly more generous surgical resection. However, to the best of our knowledge, the hypothesis that MRI can optimize surgical resection to achieve negative margins or reduce the use of re-excision has not been demonstrated to date. 39, 46, 47 In addition, the relatively low event rates in this group with an overall favorable prognosis may limit the ability to detect a true benefit (Table 2) . Certainly level I evidence from a randomized study could help to overcome the above limitations. However, the low baseline rate of local recurrence in patients without a breast MRI would necessitate a markedly higher sample size than the 755 patients in the current study. Baseline 10-year local recurrence rates of 5% or 10% would require an estimated 14,000 or 6600 patients, respectively, to detect a 20% benefit with preoperative MRI in a randomized controlled trial setting. 48 Although the results of the current study suggest that MRI is not indicated for patients with early-stage breast cancer with a favorable prognosis who are undergoing BCT, we do not have the power to comment on the usefulness of MRI in all clinically relevant subsets. Finally, the strengths of long-term follow-up data are inherently tempered by the inability to fully account for evolutions in MRI technology, technique, and interpretation, as well as the ongoing improvements in various treatment modalities (ie, surgery, radiotherapy, and systemic therapies) and
